Cargando…

Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management

Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient setting. Symptomatic presentation includes non-specific signs and symptoms of hypercalcemia, skeletal fragility, nephrolithiasis and nephrocalcinosis. The majority of individuals present at an asymptomatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Dandurand, Karel, Ali, Dalal S., Khan, Aliya A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068862/
https://www.ncbi.nlm.nih.gov/pubmed/33918966
http://dx.doi.org/10.3390/jcm10081604
_version_ 1783683102143414272
author Dandurand, Karel
Ali, Dalal S.
Khan, Aliya A.
author_facet Dandurand, Karel
Ali, Dalal S.
Khan, Aliya A.
author_sort Dandurand, Karel
collection PubMed
description Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient setting. Symptomatic presentation includes non-specific signs and symptoms of hypercalcemia, skeletal fragility, nephrolithiasis and nephrocalcinosis. The majority of individuals present at an asymptomatic stage following routine biochemical screening, without any signs or symptoms of calcium or parathyroid hormone (PTH) excess or target organ damage. Indications for surgery have recently been revised as published in recent guidelines and consensus statements. Parathyroidectomy is advised in patients younger than 50 years old and in the presence of either significant hypercalcemia, impaired renal function, renal stones or osteoporosis. Surgery is always appropriate in suitable surgical candidates, however, medical management may be considered in those with mild asymptomatic disease, contraindications to surgery or failed previous surgical intervention. We summarized the optimal medical interventions available in the care of PHPT patients not undergoing parathyroidectomy. Calcium and vitamin D intake should be optimized. Antiresorptive therapy may be used for skeletal protection in patients with an increased fracture risk. Cinacalcet, a calcimimetic agent, has been shown to effectively lower serum calcium and PTH levels. The effect of medical treatment on the reduction in fracture risk is unknown and should be the focus of future research.
format Online
Article
Text
id pubmed-8068862
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80688622021-04-26 Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management Dandurand, Karel Ali, Dalal S. Khan, Aliya A. J Clin Med Review Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient setting. Symptomatic presentation includes non-specific signs and symptoms of hypercalcemia, skeletal fragility, nephrolithiasis and nephrocalcinosis. The majority of individuals present at an asymptomatic stage following routine biochemical screening, without any signs or symptoms of calcium or parathyroid hormone (PTH) excess or target organ damage. Indications for surgery have recently been revised as published in recent guidelines and consensus statements. Parathyroidectomy is advised in patients younger than 50 years old and in the presence of either significant hypercalcemia, impaired renal function, renal stones or osteoporosis. Surgery is always appropriate in suitable surgical candidates, however, medical management may be considered in those with mild asymptomatic disease, contraindications to surgery or failed previous surgical intervention. We summarized the optimal medical interventions available in the care of PHPT patients not undergoing parathyroidectomy. Calcium and vitamin D intake should be optimized. Antiresorptive therapy may be used for skeletal protection in patients with an increased fracture risk. Cinacalcet, a calcimimetic agent, has been shown to effectively lower serum calcium and PTH levels. The effect of medical treatment on the reduction in fracture risk is unknown and should be the focus of future research. MDPI 2021-04-09 /pmc/articles/PMC8068862/ /pubmed/33918966 http://dx.doi.org/10.3390/jcm10081604 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dandurand, Karel
Ali, Dalal S.
Khan, Aliya A.
Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management
title Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management
title_full Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management
title_fullStr Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management
title_full_unstemmed Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management
title_short Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management
title_sort primary hyperparathyroidism: a narrative review of diagnosis and medical management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068862/
https://www.ncbi.nlm.nih.gov/pubmed/33918966
http://dx.doi.org/10.3390/jcm10081604
work_keys_str_mv AT dandurandkarel primaryhyperparathyroidismanarrativereviewofdiagnosisandmedicalmanagement
AT alidalals primaryhyperparathyroidismanarrativereviewofdiagnosisandmedicalmanagement
AT khanaliyaa primaryhyperparathyroidismanarrativereviewofdiagnosisandmedicalmanagement